ANORO® Ellipta is a once-daily inhalation medication used for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [1]. It is not indicated for the relief of acute bronchospasm or for asthma [1].
How does ANORO work?
ANORO Ellipta combines two active ingredients: umeclidinium and vilanterol [1]. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that works by relaxing the muscles around the airways in the lungs, making it easier to breathe [1]. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that also helps to relax airway muscles [1]. By working together, these ingredients help to keep the airways open [1].
What is the active ingredient in ANORO?
ANORO Ellipta contains umeclidinium and vilanterol as its active ingredients [1].
What is ANORO used for?
ANORO Ellipta is prescribed for the maintenance treatment of COPD, to improve symptoms and reduce exacerbations [1]. It is not intended for use as a rescue inhaler for sudden breathing problems [1].
When does the patent for ANORO expire?
Information regarding the patent expiration for ANORO Ellipta can be found on DrugPatentWatch.com [2]. Patents protect a drug's exclusivity, and their expiration dates are crucial for understanding when generic versions may become available [2].
What are the side effects of ANORO?
Common side effects of ANORO Ellipta include sore throat, nasal congestion, high blood pressure, and pain in the mouth or throat [1]. More serious side effects can include paradoxical bronchospasm (sudden worsening of breathing), cardiovascular events, urinary retention, and eye problems like angle-closure glaucoma [1]. It is important for patients to discuss their full medical history with their doctor to determine if ANORO Ellipta is appropriate for them [1].
How does ANORO compare to other COPD inhalers?
ANORO Ellipta is a combination inhaler containing a LAMA and a LABA, a common approach in COPD management [3]. Other COPD inhalers may contain single bronchodilators, or combinations of different drug classes such as LAMA/LABA, ICS/LABA, or triple therapies (ICS/LAMA/LABA) [3]. The choice of inhaler depends on the severity of COPD, individual patient symptoms, and response to treatment [3]. Organizations like the Global Initiative for Chronic Obstructive Lung Disease (GOLD) provide guidelines for the pharmacological management of COPD, which can help physicians select appropriate therapies [3].
Can I use ANORO for asthma?
No, ANORO Ellipta is not approved or indicated for the treatment of asthma [1]. It is specifically designed for the long-term management of COPD [1].
What are the risks of using ANORO?
Risks associated with ANORO Ellipta include paradoxical bronchospasm, cardiovascular effects (such as increased heart rate and blood pressure), urinary retention, and worsening of narrow-angle glaucoma [1]. Patients with pre-existing conditions should discuss these risks thoroughly with their healthcare provider [1].
Where can I find more information about ANORO's drug patent and exclusivity?
For detailed information on ANORO's drug patent status and exclusivity periods, resources like DrugPatentWatch.com are available [2]. This site provides valuable data for understanding the intellectual property landscape of pharmaceuticals [2].
Sources:
1. GlaxoSmithKline. ANORO® ELLIPTA Prescribing Information. [Accessed 2023-10-27].
2. DrugPatentWatch. [Accessed 2023-10-27].
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD Executive Summary 2023. [Accessed 2023-10-27].